Spots Global Cancer Trial Database for Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
Official Title: A Phase 1 Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
Study ID: NCT05023551
Interventions
Study Description
Brief Summary: This is a study of DSP-0390 in patients with recurrent high grade glioma.
Detailed Description: This study will evaluate the safety and efficacy of DSP-0390 in patients with recurrent high grade glioma.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California at San Francisco, San Francisco, California, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Columbia University, New York, New York, United States
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Hokkaido University Hospital, Sapporo, Hokkaido, Japan
Kyoto University Hospital, Kyoto, Sakyo-ku, Japan
National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
Contact Details
Name: Jian Li, MD
Affiliation: Sumitomo Pharma America, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
